Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


Antiinfectives are also classified in the following groups:
A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R02AB Antibiotics
S03 Eye and ear preparations with antiinfectives
Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use.
Inhaled antiinfectives are classified in J.

The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).


This group comprises antibacterials for systemic use, except antimycobacterials, which are classified in J04. The antibacterials are classified according to their mode of action and chemistry.
Combinations of two or more systemic antibacterials from different third levels are classified in J01R, except combinations of sulfonamides and trimethoprim, which are classified at a separate 4th level, J01EE.
Combinations of antibacterials and tuberculostatics are classified in J04AM.
Combinations of antibacterials with other drugs, including local anesthetics or vitamins, are classified at separate 5th levels in the respective antibacterial group by using the 50-series.
Inhaled antiinfectives are classified here based on the fact that preparations for inhalation can not be separated from preparations for injection.


This group comprises antibacterials with various modes of action not classified in the preceding groups.

J01XA Glycopeptide antibacterials

This group comprises glycopeptide antibacterials, inhibiting the cell wall synthesis of gram positive bacteria. Lipoglycopeptide antibacterials are also included in this group. Teicoplanin and intravenous preparations of vancomycin are classified in this group. Oral formulations containing vancomycin are classified in A07A.

J01XB Polymyxins

This group comprises polymyxin antibacterials acting on the bacterial cytoplasm membrane. Oral formulations containing colistin are classified in A07A.

J01XC Steroid antibacterials

This group comprises steroid antibacterials, inhibiting the binding of bacterial transfer-RNA and the 50-S part of the ribosomes.

J01XD Imidazole derivatives

This group comprises imidazole antibacterials acting through active metabolites in anaerobic bacteria. Only formulations for parenteral use of e.g. metronidazole are classified in this group. Oral formulations and suppositories of imidazole derivatives are classified in P01 - Antiprotozoals. Pessaries are classified in G01 - Gynecological antiinfectives and antiseptics.

The DDDs for the parenteral imidazole formulations are based on the treatment of anaerobic bacteria infections.

J01XE Nitrofuran derivatives

Preparations, which in addition contain a urine acidifier, such as vitamin C, calcium- or ammonium chloride, are classified at the plain 5th levels.
Nitrofurantoin in combination with phenazopyridine is classified in J01XE51.

The DDDs are generally based on the treatment of acute urinary tract infections.

J01XX Other antibacterials

Preparations, which in addition contain a urine acidifier, such as vitamin C, calcium- or ammonium chloride, are classified at the plain 5th levels.

The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.
The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.
The DDD for methenamine is based on prophylaxis of urinary tract infections. The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.

Last updated: 2023-01-23